Iconoclast thanks for your post. I agree, to one degree or another, with your points however I think some investors who walked away with failed ph3 (pt6) may revisit RVX with today's news. As far as keeping the lights on (pt8), I think today's news should make any deals in this regard a little easier to facilitate. I almost wonder if we may see another warrant conversion incentive program arise. Since nothing has been posted on SEDAR regarding the previously announced program I am assuming it was a flop which to me is a bit of a head scratcher since most CEO's would have had meaningful expressions of interest before even going through the exercise of bringing the program into existence. Not to mention the lousy optics of needlessly announcing a program which nobody is interested in. 

I was once told by an individual who is well connected in senior big pharma that as far as buying new technology goes, that no one is interested until many are interested. It would be great if today's news is enough to push one or more BPs into serious interest mode. It would seem that BT status derisks the program somewhat and adds some clarity as to projecting when a buyer could expect to see revenue from a successful completion of the apabetalone clinical program. Given that at the AGM Don told me that EV value was then $4B (down from an $8B sale price if topline was hit) one could assume that BT status adds at to post topline EV. Just as in any market if there are a number of interested buyers I could see RVX being sold at a premium to EV if there is only one perhaps it might go for a discount to EV. I for one just hope RVX gets sold.